Document is current

Article History

Received: 20 August 2025

Revised: 22 October 2025

Accepted: 23 October 2025

First Online: 10 November 2025

Declarations

:

: Mitsumasa Watanabe and Taku Tsukamoto declare no conflicts of interest. Jun Takizawa has received consulting fees (including expert testimony) from Janssen, AstraZeneca, and AbbVie; has received research funding from AstraZeneca, Mitsubishi Tanabe, AbbVie, BeiGene, Novartis, Chugai, Kyowa Kirin, Nippon Kayaku, Janssen, Eli Lilly, and Asahi Kasei; and has received honoraria from Janssen, AstraZeneca, AbbVie, Novartis, BeiGene, Chugai, Kyowa Kirin, and Nippon Kayaku. Tomomi Toubai has received honoraria from Takeda and research grants from IQVIA, AbbVie, Meiji Seika Pharma, Novartis, Chugai, Pfizer, Sanofi, Amgen, Incyte, and Zenyaku. Dai Maruyama has served as consultant or adviser for Janssen, AstraZeneca, Chugai, AbbVie, Genmab, Sanofi, BMS, and Pfizer; has received honoraria from Ono, Nippon Shinyaku, Janssen, Mundipharma, Eisai, Chugai, Kyowa Kirin, MSD, Zenyaku, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Pfizer, and Roche; and has received research grants from Ono, Janssen, Eisai, Chugai, Roche, Kyowa Kirin, MSD, Zenyaku, Sanofi, Symbio, Takeda, AbbVie, AstraZeneca, BMS, Genmab, Novartis, Otsuka, Taiho, Pfizer, and Astellas. Takahiro Kumode has received honoraria from Janssen, AstraZeneca, AbbVie, Genmab, BeiGene, and Ono Pharmaceutical. Noriko Fukuhara has received research grants from AbbVie, Kaiwa Pharma, Chugai Pharma, and Ono Pharma and is an editor of the International Journal of Hematology. Natsumi Ogawa, Natsuko Satomi, Yasuko Nishimura, Hideyuki Honda, and Brenda Chyla are employees and stockholders of AbbVie. Koji Izutsu has received research grants from AstraZeneca, AbbVie, Incyte, Bristol Myers Squibb, Novartis, Yakult, Daiichi Sankyo, Chugai, BeiGene, Genmab, LOXO Oncology, Otsuka, and Regeneron.

: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link: then select “Home”.